Citations

Clear

4847 citation(s) found for "Yu, Eric".

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.
Chuma, Stacey, Sam, Amy, Leduc, Renee, Nelson, Marybeth, Warren, Diane, Jacobsen, Eric D. , Richardson, Paul G. , Ghobrial, Irene M. , O’Connor, Kelly E. , Harris, Brianna , Soumerai, Jacob D. , DeAngelo, Daniel J. , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Witzig, Thomas E. , Treon, Steven P.

Mayo Clinic

Blood | April 19, 2020 | Volume: 112 | Issue: 11 | Pages: 1011-1011

10.1182/blood.v112.11.1011.1011 Get It

Abstract INTRODUCTION: Previous studies have demonstrated the clinical activity of the mTOR inhibitor RAD001 in low- grade lymphomas. Our preclinical studies demonstrated activity of mTOR inhibitors in Waldenstrom Macroglobulinemia (WM) cell lines and patient samples. This phase II study aimed to determine safety and activity of the oral mTOR inhibitor RAD001 (Novartis Pharmaceutical, MA) in patients with relapsed or refractory WM. METHODS: Patients who had at least one previous therapy for WM, and who had symptomatic relapsed or refractory disease were eligible. NCI CTCAE v3.0 was used for toxicity assessment. All patients received daily RAD001 at 10 mg. A cycle was considered 28 days. Patients were allowed to stay on therapy until progression of disease or excessive toxicity. This study was conducted in a collaborative effort between Dana Farber Cancer Institute (DFCI) and Mayo Clinic College of Medicine. Here, we report the data on the patients accrued at DFCI. RESULTS: 19 pts (15 men and 4 women) have been treated to date. All patients had symptomatic disease and required therapy. The median number of lines of prior treatment was 3 (range 1 – 5) including included rituximab, nucleoside analogues (fludarabine or 2-CDA), combination chemotherapy (e.g. CHOP, CVP), chloramucil, and bortezomib. The median IgM at baseline was 3330 mg/dL (range 1010– 7410). The median follow on RAD001 was 8 months (range 3 – 22 months). Eighteen pts are currently evaluable for response. Best responses to RAD001 after 2 cycles using IgM monoclonal protein were as follows: partial remission in 8 (44%), minimal response in 5 (28%). Progressive disease occurred in 4 (22%) and stable disease occurred in 1 (6%). The overall response rate (PR+MR) was 72%. The median duration of response has not been reached (3–22+ months). Patients tolerated therapy well without significant toxicities. Grade 3 and 4 toxicities included grade 4 thrombocytopenia in 1 patient, grade 3 pneumonia in 1 patient, grade 3 hyperglycemia in 1 patient and grade 3 mucositis in 1 patient. Other adverse events of grade 2 or lower included nail cracking, mucositis, diarrhea, and fatigue. Attributable toxicities otherwise proved manageable with appropriate supportive care, and RAD001 was generally well tolerated. One patient enrolled on the study withdrew consent and changed to hospice care within 3 weeks of therapy, and passed away due to disease progression. CONCLUSIONS: The use of the oral RAD001 single agent RAD001 in patients with relapsed or refractory WM was welltolerated and demonstrated significant activity achieving an overall response rate in 72% of patients. Future studies of combination of this agent with rituximab and bortezomib are currently being planned.
The Effect of Subsystolic Regional Circulatory Occlusion on Blood Pressure and Systemic Vascular Resistance in Men and Women during Exercise
Villarraga, Nicolas , Randall, Nicholas R. , Bruhn, Eric J., Olson, Thomas P. , Smith, Joshua R.

Mayo Clinic

The FASEB Journal | April 17, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.03441 Get It

Introduction The exercise pressor reflex contributes to cardiovascular regulation during exercise. The primary components of the exercise pressor reflex response are the mechanically and metabolically sensitive skeletal muscle afferents (group III and IV, respectively). Experimentally, subsystolic regional circulatory occlusion (SubRCO) leads to venous distention, stimulating primarily group III afferents, thereby augmenting the exercise pressor reflex. Previous studies have reported sex differences in the metaboreflex induced exercise pressor reflex induced cardiovascular responses. Specifically, pre‐menopausal women, compared to age‐matched men, were found to have attenuated cardiovascular responses with mechanoreflex stimulation. However, it is unclear if sex differences are also present in the cardiovascular responses during exercise with locomotor limb venous distention. Therefore, the purpose of this study was to determine the influence of SubRCO during submaximal exercise in men and women. We hypothesized that women will have attenuated increases in mean arterial pressure (MAP) and systemic vascular resistance (SVR) than men during exercise with SubRCO. Methods Twelve men and thirteen women completed two study visits (Age: M: 30±6vs. W: 27±8yrs, p>0.05; BMI: M: 25.4±3.6 vs. W: 22±3 kg/m 2 , p<0.05). The first visit consisted of a peak exercise ergometry test. The second visit consisted of constant‐load cycle ergometry at 30% peak workload with different SubRCO pressures via bilateral upper thigh pressure cuffs. The cuffs remained uninflated (0 mmHg) (CTL) during the first three min of exercise, then were intermittently inflated to 20, 40, 60, 80, or 100 mmHg for two minutes (randomized order). Each inflation period was followed by a 2minute deflation period where the participant continued to exercise. Cardiacoutput (Q) and MAP were measured via continuous hemodynamic photoplethysmography and systemic vascular resistance (SVR) was calculated. Data were reported as delta changes from CTL. Results Compared to 0 mmHg, MAP increased with SubRCO inflation pressures of 60, 80, and 100mmHg in men and women during submaximal exercise (all, p<0.05); however, no differences were present between groups (60 mmHg: M: 6.2±4.2 vs. W: 8.0±5.2; 80mmHg: M: 11.6±5.5 vs. W: 15.1±4.8; 100 mmHg: M: 18.2±6.6 vs. W: 20.5±7.2 mmHg(all, p>0.05)). Similarly, SVR increased with cuff inflation pressures of60, 80, and 100 mmHg compared to 0 mmHg in men and women (p<0.05), while no differences existed between groups (60 mmHg: M: 0.3±0.4 vs W: 0.4±0.5;80 mmHg: M: 0.9±0.5 vs W: 1.1± 0.9; 100 mmHg M: 1.3±0.8vs W: 1.5±0.8mmHg/L/min (all, p>0.05)). In contrast, Q did not change with cuff inflation pressures of 20, 40, 60, 80, or100 mmHg compared to 0 mmHg in men or women during submaximal exercise(p>0.05). Conclusion In contrast to our hypothesis, the MAP and SVR responses were not different between men and women with SubRCO during submaximal exercise. Our findings suggest that sex differences are not present in the cardiovascular response to low‐intensity constant‐load exercise with stimulation of the exercise pressor reflex via lower limb venous distention.
The Effect of Menopause Status on the Skeletal Muscle Metaboreflex.
Villarraga, Nicolas , Randall, Nicholas R. , Bruhn, Eric J., Olson, Thomas P. , Smith, Joshua R.

Mayo Clinic

The FASEB Journal | April 17, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.03405 Get It

Introduction It is well established that the exercise pressor reflex contributes to cardiovascular control (e.g. mean arterial pressure (MAP)) during exercise. One arm of the exercise pressor reflex includes the metabolically sensitive group IV afferents (i.e. metaboreflex). The metaboreflex‐induced cardiovascular responses to exercise are incompletely understood, especially in women across the aging spectrum. For example, post‐menopausal women have greater increases in MAP and systemic vascular resistance (SVR) during locomotor muscle exercise compared to pre‐menopausal women. However, it is unclear if an exaggerated metaboreflex arising from the locomotor muscles is contributing to these cardiovascular adjustments with exercise in post‐menopausal women. We hypothesized that 1) post‐menopausal women will have an augmented MAP response with isolated metaboreflex activation compared to pre‐menopausal women and 2) the exaggerated increase in MAP in the post‐menopausal women will be primarily due to greater increases in SVR. Methods Pre‐ (n= 10, 25±3yrs, 24±3 kg/m 2 ) and post‐menopausal women (n=12, 58±4yrs, 24±3 kg/m 2 ) performed 2 sessions of cycling exercise at 20 W for 5 min with bilateral upper thigh pressure tourniquets inflated to 90 mmHg. At end exercise, the recovery was randomized to post‐exercise circulatory occlusion (PECO) to isolate the metaboreflex (via bilateral upper thigh pressure tourniquets rapidly inflated to suprasystolic pressure for 2 min) or normal recovery (NR) without intervention. Systolic and diastolic blood pressure were measured via manual sphygmomanometry and MAP was calculated. Cardiac output was measured via open circuit acetylene wash‐in and systemic vascular resistance (SVR) was calculated. Data is reported as the absolute change from rest to recovery. Results MAP was elevated during PECO compared to NR in both groups (p<0.05), while MAP during PECO was greater in post‐ compared to pre‐menopausal women (20±9 vs. 13±5 mmHg, respectively) (p<0.05). Similarly, SVR was elevated during PECO compared to NR in both groups (p<0.05), while SVR was greater during PECO in post‐ compared to pre‐menopausal women (5±3 vs. 3±1 mmHg/L/min, respectively) (p<0.05). In contrast, cardiac output was not different between NR and PECO in either pre‐ (NR: 0.3±1 vs. PECO: −0.2±1 L/min) and post‐menopausal (NR: −0.1±1 vs. PECO: −0.7±0.9 L/min) (all, p>0.05). Conclusion These data demonstrate that isolated metaboreflex stimulation following whole‐body exercise results in exaggerated increases in MAP and SVR in post‐ compared to pre‐menopausal women. These data suggest that exercise pressor reflex‐mediated control of MAP during exercise is accentuated in post‐menopausal women with menopause status.
Combined Influence of Inspiratory Loading and Subsystolic Cuff Inflation on Blood Pressure: Impact of Inspiratory Muscle Training
Berg, Jessica, Villarraga, Nico, Bruhn, Eric J., Olson, Thomas P. , Smith, Joshua R.

Mayo Clinic

The FASEB Journal | April 17, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.03274 Get It

Objective Cardiovascular adjustments to exercise, including increases in blood pressure (MAP) and heart rate, occur in response to several neural mechanisms. Specifically, stimulation of respiratory (via inspiratory loading (IL)) and locomotor muscle (via subsystolic cuff inflation (CUFF)) neurologic feedback via group III/IV afferents augments the MAP response during exercise. Further, we have recently shown that simultaneous stimulation of the respiratory and locomotor muscle afferents during exercise potentiates the MAP increase compared to when these reflexes are stimulated individually. To date, interventional strategies to attenuate the augmented MAP during IL+CUFF have not been investigated. Previous studies have shown that inspiratory muscle training (IMT) attenuates the IL‐induced increase in MAP at rest in healthy adults. We hypothesized that 8 weeks of IMT will attenuate the IL+CUFF‐induced increase in MAP during exercise in healthy adults. Methods Twenty adults were recruited and randomized to the IMT (n=10) or sham group (n=10). Participants performed 8 weeks of IMT twice a day, 7 days a week at 50% (IMT) or 10% (sham) maximum inspiratory pressure (MIP). On separate visits, participants performed an incremental cycling test to volitional fatigue and a 10 min cycling exercise bout at 40% maximal oxygen uptake Pre‐ and Post‐IMT. The exercise bout consisted of 5 min of spontaneous breathing followed by 5 min of voluntary hyperventilation (i.e. breathing frequency of 40 breaths per min) with IL (30% MIP) and bilateral locomotor subsystolic cuff inflation (80 mmHg). Systolic and diastolic blood pressure (SBP and DBP, respectively) were measured using manual sphygmomanometry and MAP was calculated. SBP and MAP were reported as the change from rest. Dyspnea was measured via Borg scale (1–10). Results After 8 weeks, MIP increased in the IMT (Pre: 99±26 vs. Post: 127±26 cmH 2 O, p<0.05), but not the sham group (Pre: 126±29 vs. Post: 129±28 cmH 2 O, p>0.05). Pre‐IMT, the increase in MAP with IL+CUFF was not different between groups (IMT: 28±6 vs. sham: 31±7 mmHg) (p>0.05). Post‐IMT, the increase in MAP with IL+CUFF was attenuated in IMT, but not sham (IMT: 23±7 vs. sham: 32±5 mmHg) (p<0.05). Pre‐IMT, the increase in SBP with IL+CUFF was not different between groups (IMT: 49±12 vs. sham: 53±16 mmHg) (p>0.05). Post‐IMT, the increase in SBP with IL+CUFF was attenuated in IMT, but not sham (IMT: 42±12 vs. sham: 57±14 mmHg) (both, p<0.05). The increase in DBP with IL+CUFF was not different between groups Pre or Post‐IMT (both, p>0.05). Lastly, dyspnea was not different Pre‐IMT between groups (IMT: 4±3 vs. sham: 4±2 Borg (1–10)) (p>0.05), but was lower in the IMT, but not sham Post‐IMT (IMT: 2±2 vs. sham: 4±1 Borg (1–10)) (p<0.05). Conclusions These data demonstrate that IMT attenuates the MAP response when the respiratory and locomotor afferents are stimulated simultaneously. These findings have important clinical implications for populations that exhibit exaggerated respiratory and locomotor muscle reflexes during exercise. Support or Funding Information This work was supported by the National Institutes of Health [HL126638 to TPO] and American Heart Association [18POST3990251 to JRS].
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Sexton, Rachael, Lentzsch, Suzanne , Abidi, Muneer H. , Voorhees, Peter M. , Cohen, Adam D. , Rohren, Eric , Heitner, Stephen B. , Kelly, Kevin R. , Mackler, Niklas J., Baer, David, Hoering, Antje , Durie, Brian G.M. , Orlowski, Robert Z. , Abidi, Muneer H , Cohen, Adam D , Heitner, Stephen , Orlowski, Robert Z. , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | April 16, 2020 | Volume: 26 | Issue: 15 | Pages: 3969-3978

10.1158/1078-0432.ccr-19-1997 | PMID 32299820 Get It

Abstract Purpose: Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. Patients and Methods: We report the Southwest Oncology Group randomized phase II trial (S1304) comparing twice weekly low-dose (27 mg/m2; arm 1) to high-dose carfilzomib (56 mg/m2; arm 2), both with dexamethasone, administered for 12 cycles (11 months) for relapsed and/or refractory multiple myeloma with up to six prior lines of therapy (NCT01903811). The primary endpoint was progression-free survival (PFS), and patients on arm 1 could cross-over to arm 2 after progression on treatment. Results: Among 143 enrolled patients, of whom 121 were eligible and analyzable, the overall response rate was 42.8%, with no significant difference between the arms (P = 0.113). Also, neither the median PFS [5 months and 8 months, respectively; HR, 1.061; 80% Wald confidence interval (CI), 0.821–1.370; P = 0.384] nor the median overall survival were significantly different (26 and 22 months, respectively; HR, 1.149, 80% Wald CI, 0.841–.571; P = 0.284). Sixteen patients crossed over to arm 2 with a median PFS benefit of 3 months. Certain adverse events (AE) were more frequent in arm 2, including fatigue, thrombocytopenia, and peripheral neuropathy, but there was no significant difference in cardiopulmonary AEs. Conclusions: This randomized trial did not support a benefit of fixed duration, twice weekly 56 mg/m2 dosing of carfilzomib over the 27 mg/m2 dose for the treatment of relapsed and/or refractory multiple myeloma. However, treatment to progression in earlier patient populations with high-dose carfilzomib using different schedules should still be considered as part of the standard of care.
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Holmes, DaJuanicia N. , Pieper, Karen S. , Ezekowitz, Michael D. , Fonarow, Gregg C. , Gersh, Bernard J. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , Mendelson, R. A., NEUTEL, J, Pan, Dengji, Poock, James J., Raffetto, J.D., Greengold, R., Roan, P G, Saba, F., Sackett, Melanie K., Schneider, R., Seymour, Zachary , Shanes, Jeffrey G., Smiley, Nasser, Smith, David H. , Snipes, C., Sotolongo, Rodolfo, Staniloae, Cezar , Stoltz, S., Suresh, D.P. , Tak, Tahir , Tannenbaum, A., Turk, Samir, Vora, Kishor, Randhawa, P., Zebrack, James S., Silva, Eduardo , Riley, Edward T., Weinstein, D., Vasiliauskas, Tomas, Goldbarg, Seth , Yarlagadda, Chakri, Laurion, D., Osunkoya, A., Burns, Richéal , Castor, Tatsiana , Luttman, C., Anton, Stephen D. , McGarvey, Jeremy R., Guthrie, Robert D., Deriso, George T., Flood, Raymond, Fleischer, L H, Fierstein, J.S., Jacobs, George B., Adjei, Nasser, Akyea-Djamson, Ayim, Bacon, Jenny , Bedwell, Noel W., Berger, PB, Berry, Joni I., Bhagwat, Ravi, Boccalandro, Fernando , Capó, Jaïr Dilmé, Kapadia, Sumit, Casanova, Rene, Morriss, J.E., Elsen, J., Farsad, Ramin, Fox, David J. , Frandsen, Brad, Gelernt, M., Hall, Cassandra L. , Hotchkiss, David R. , Ip, J., Jaffrani, Naseem, Kazmierski, John F., Waxman, F., Kneller, G. Larsen, Labroo, Ajay, Jaffe, Bernard M., Lebenthal, Mark, Lillestol, Michael, Leclerc, Kenneth M. , Maccaro, Paul, Mayer, Nolan, Kozłowski, J , Benjamin, Sanford P., Detweiler, Robert, Igic, Petar, Jackson, Tatum, Pappas, Janine, Littlefield, Ryan , Frey, Anna , Vranian, Robert B., Long, W., Grena, Paul, Arouni, Amy , Quinn, John , Blonder, Ronald, Snyder, H., Slabic, S., Cohen, Kenneth D., Walthall, W. W., Snoddy, Brian, Alvarado, Olga Franco, Leach, Corinne L., Rothman, Steven A., Olatidoye, Abiodun G, Almahameed, Soufian , Rosenthal, Shelly, Reiter, William M., Thompson, T., Thew, Stephen, Kobayashi, Junji , Williams, M., Kramer, Joel H. , Latif, Sidrah , Rhee, B., Ruiz-Serrano, D., Stringam, Stanley, Wolok, K., Focil, Augusto, Butman, Samuel, Ingersoll, Henry, Borge, R. P., Al-Saghir, Y., Farris, Neil, Shore, Karen, Gornick, C., Eilat, P., Paliwal, Y., Mitra, Rito , Jingo, Ahmad, Aslam, Asma , Watson, Robert, Voyce, Stephen , Turakhia, Mintu P. , Goytia-Leos, D., Lurie, Miriam, Mallis, G., Strobel, John, Fisher, D M, Atieh, Mutaz I., Drabick, Andrew, Harman, Ece, Ashcraft, B., Krista, M., Videlefsky, A., Zayas, E. Rivera, Tan, A.E., Gersh, Bernard J , Turakhia, Mintu P , Steinberg, Benjamin A. , Allen, Larry A. , Chan, Paul S. , Freeman, James V. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Mendelson, R., AL-NAHHAS, ADIL M. , Padanilam, B., Pan, D., Raffetto, J., Roan, P., Sackett, M., Seymour, Z., Shoemaker, J. Kevin , Simms, V., Tak, T., Riley, E., Weinstein, D., Hayward, D., Burns, R., Spiller, D., McGarvey, J., Guthrie, R., Flood, R., Aggarwal, R., Jacobs, G., Alfieri, A., Bacon, J., Berger, P., Berry, J., Bloom, S., Kapadia, S., Casanova, R., Christensen, T., Fox, D., Gill, S., Grubb, Søren , Hall, C., Harris, H., Hotchkiss, D., Jones, A., Lee, David S. , Kozlowski, J., Benjamin, S., Detweiler, R., Jackson, T., Littlefield, R., Long, W., Quinn, J., Browne, Kevin D. , Forman, Steven L. , Ebinger, Martin , Williams, David Michael , Stein, R., Kirkland, S., Cohen, K., Walthall, W., Davis, Keith L. , Alvarado, O., Leach, C., Sharma, Anand , Sutter, G., Reiter, W., Kobayashi, J., Kramer, J., Latif, S.A., Adler, Alma J , Butman, Samuel M. , Coats, Paul , Shore, K., Schwartz, M.B., Quinlan, E., Mitra, R., Aslam, A.A., Lurie, M., Atwater, Brett D. , Murray, John M. , Fisher, D., Landes, Reid D. , Harman, E., Zayas, E. Rivera

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 16, 2020 | Volume: 13 | Issue: 5 | Pages: No page available

10.1161/circep.119.007775 | PMID 32298144 Get It

Background: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. Methods: We assessed factors associated with a 1-year increase in the Atrial Fibrillation Effect on Quality-of-Life score of 1 SD (≥18 points; 3× clinically important difference), among outpatients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I registry. Results: Overall, 28% (181/636) of patients had such a hrQoL improvement. Compared with patients not showing large hrQoL improvement, they were of similar age (median 73 versus 74, P =0.3), equally likely to be female (44% versus 48%, P =0.3), but more likely to have newly diagnosed AF at baseline (18% versus 8%; P =0.0004), prior antiarrhythmic drug use (52% versus 40%, P =0.005), baseline antiarrhythmic drug use (34.8% versus 26.8%, P =0.045), and more likely to undergo AF-related procedures during follow-up (AF ablation: 6.6% versus 2.0%, P =0.003; cardioversion: 12.2% versus 5.9%, P =0.008). In multivariable analysis, a history of alcohol abuse (adjusted OR, 2.41; P =0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point increase and >65 mm Hg; P =0.04) were associated with large improvements in hrQoL at 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve ( P <0.05 for each). Conclusions: In this national registry of patients with AF, potentially treatable AF risk factors are associated with large hrQoL improvement, whereas less reversible conditions appeared negatively associated with hrQoL improvement. Understanding which patients are most likely to have large hrQoL improvement may facilitate targeting interventions for high-value care that optimizes patient-reported outcomes in AF. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Long‐term causes of death among pediatric patients with cancer
Horn, Samantha R. , Stoltzfus, Kelsey C. , Mackley, Heath B., Lehrer, Eric J. , Dandekar, Smita , Fox, Edward , Rizk, Elias , Trifiletti, Daniel M. , Rao, Pooja , Trifiletti, Daniel M , Rao, Pooja M , Zaorsky, Nicholas G , Horn, Samantha R. , Zhou, Shouhao , Zaorsky, Nicholas G.

Mayo Clinic

Cancer | April 16, 2020 | Volume: 126 | Issue: 13 | Pages: 3102-3113

10.1002/cncr.32885 | PMID 32298481 Get It

Background The objectives of this study were to characterize the risk of death (1) from the primary cancer vs competing cause of death; and (2) from various causes of death vs the general poplation. The relative risk of death after a pediatric cancer diagnosis versus the general population and the risk of death from a primary cancer diagnosis versus competing causes of death. Methods This retrospective, population‐based study used the Surveillance, Epidemiology, and End Results database (1980‐2015) and included patients aged 0 to 19 years at the time of diagnosis. Observed deaths were calculated; the risk of death versus the general population was assessed with standardized mortality ratios (SMRs). Competing risk models for the cause of death were performed. Results There were 58,356 patients who were diagnosed, and the mortality rate was 22.8%. To assess causes of death, 6996 patients who died during the study period were included (45,580 total person‐years at risk): 5128 (73%) died of their primary cancer, and 1868 (27%) died of a competing cause. Among all patients, the rate of death from the index cancer was higher than the rate of death from another cause within the first 5 years after diagnosis. The risk of death from a nonprimary cancer began to supersede the rate of death from the primary cancer 10 years after diagnosis for patients with germ cell tumors, lymphomas, and sarcomas. SMRs for the primary cancer were highest within the first 5 years after diagnosis for all cancers (SMRs, 100‐50,000; P < .0001). The risk of death from competing causes (heart disease, suicide, and sepsis) was elevated (SMR, >100; P < .001). The risk of dying of heart disease was high, especially for patients with astrocytomas (SMR, 47.84; 95% confidence interval [CI], 27.87‐76.59) and neuroblastomas (SMR, 98.59; 95% CI, 47.28‐181.32). The risk of dying of suicide was high in most patients, particularly for those with osteosarcomas (SMR, 111.40; 95% CI, 2.82‐620.69), Hodgkin lymphomas (SMR, 62.35; 95% CI, 34.89‐102.83), and gonadal germ cell tumors (SMR, 28.97; 95% CI, 12.51‐57.09). Conclusions The cause of death for patients with gonadal germ cell tumors, lymphomas, and sarcomas is more commonly a secondary cancer or noncancerous cause than the primary disease; their risk of death from competing causes (heart disease, suicide, and sepsis) rises throughout life.
Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study
Foucar, Kathryn , Hsi, Eric D. , Wang, Sa A. , Rogers, Heesun J. , Hasserjian, Robert P. , Bagg, Adam , George, Tracy I. , Peterson, LoAnn, Morice, William G. , Bueso‐Ramos, Carlos E. , Group, for the Bone Marrow Pathology, George, Tracy I , Hsi, Eric D , Bassett, Roland L. , Morice, William George , Arber, Daniel A. , Orazi, Attilio , Group, for the Bone Marrow Pathology

Mayo Clinic

International Journal of Laboratory Hematology | April 16, 2020 | Volume: 42 | Issue: 4 | Pages: 418-422

10.1111/ijlh.13212 | PMID 32297416 Get It

AbstractEnumeration of blasts and promonocytes is essential for World Health Organization (WHO) classification of myelomonocytic neoplasms. The accuracy of distinguishing blasts, promonocytes and monocytes, including normal vs abnormal monocytes, remains controversial. The objective of this analysis is to assess concordances between experienced hematopathologists in classifying cells as blasts, promonocytes, and monocytes according to WHO criteria. Each of 11 hematopathologists assessed glass slides from 20 patients [12 with chronic myelomonocytic leukemia (CMML) and 8 with acute myeloid leukemia (AML)] including blood and BM aspirate smears, and limited nonspecific esterase (NSE) stains. All cases were blindly reviewed. Fleiss’ extension of Cohen's kappa for multiple raters was used on these variables, separately for peripheral blood (PB) and bone marrow (BM). Spearman's rank correlation was used to assess correlations between each pair of hematopathologists for each measurement. For the classification based on the sum of blasts and promonocytes in the BM, Fleiss’ kappa was estimated as 0.744. For PB, categorizing patients according to the sum of blasts and promonocytes, Fleiss’ kappa was estimated as 0.949. Distinction of abnormal monocytes from normal monocytes in PB did not achieve a good concordance and showed strong evidence of differences between hematopathologists (P < .0001). The hematopathologists achieved a good concordance rate of 74% in CMML vs AML classification and a high k rate, confirming that criteria for defining the blasts equivalents (blasts plus promonocytes) could be applied consistently. Identification of monocyte subtypes (abnormal vs normal) was not concordant. Our results support the practice of combining blasts/promonocytes into a single category.
Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
Patnaik, Mrinal M. , Sallman, David A. , Mangaonkar, Abhishek A. , Heuer, Rachel, Hirvela, Jeffery, Zblewski, Darci, Al‐Kali, Aref , Binder, Moritz , Balasis, Maria E. , Newman, Hannah , Letson, Christopher T. , Gangat, Naseema , Komrokji, Rami S. , Tefferi, Ayalew , Lo, Adrian , Shih, Ted, Durrant, Cameron, Padron, Eric , Binder, Moritz , Komrokji, Rami S , Balasis, Maria , Newman, Hannah , Kruer, Traci , List, Alan F.

Mayo Clinic

Blood | April 15, 2020 | Volume: 136 | Issue: 7 | Pages: 909-913

10.1182/blood.2019004352 | PMID 32294158 Get It

In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.
Review: Mathematical Modeling of Prostate Cancer and Clinical Application
Phan, Tin , Crook, Sharon , Bryce, Alan H. , Kostelich, Eric J. , Kuang, Yang , Bryce, Alan H , Maley, Carlo C.

Mayo Clinic

Applied Sciences | April 15, 2020 | Volume: 10 | Issue: 8 | Pages: 2721

10.3390/app10082721 Get It

We review and synthesize key findings and limitations of mathematical models for prostate cancer, both from theoretical work and data-validated approaches, especially concerning clinical applications. Our focus is on models of prostate cancer dynamics under treatment, particularly with a view toward optimizing hormone-based treatment schedules and estimating the onset of treatment resistance under various assumptions. Population models suggest that intermittent or adaptive therapy is more beneficial to delay cancer relapse as compared to the standard continuous therapy if treatment resistance comes at a competitive cost for cancer cells. Another consensus among existing work is that the standard biomarker for cancer growth, prostate-specific antigen, may not always correlate well with cancer progression. Instead, its doubling rate appears to be a better indicator of tumor growth. Much of the existing work utilizes simple ordinary differential equations due to difficulty in collecting spatial data and due to the early success of using prostate-specific antigen in mathematical modeling. However, a shift toward more complex and realistic models is taking place, which leaves many of the theoretical and mathematical questions unexplored. Furthermore, as adaptive therapy displays better potential than existing treatment protocols, an increasing number of studies incorporate this treatment into modeling efforts. Although existing modeling work has explored and yielded useful insights on the treatment of prostate cancer, the road to clinical application is still elusive. Among the pertinent issues needed to be addressed to bridge the gap from modeling work to clinical application are (1) real-time data validation and model identification, (2) sensitivity analysis and uncertainty quantification for model prediction, and (3) optimal treatment/schedule while considering drug properties, interactions, and toxicity. To address these issues, we suggest in-depth studies on various aspects of the parameters in dynamical models such as the evolution of parameters over time. We hope this review will assist future attempts at studying prostate cancer.